文献速递冠心病

托珠单抗对心肌梗死冠状动脉微血管及内皮功能的影响

Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.
PubMed 文献 · Heart · 2017-04-21

本亚组研究纳入非ST段抬高型心肌梗死患者,评估单次托珠单抗对冠状动脉血流储备(CFR)及内皮细胞活化标志物的影响。托珠单抗未影响住院期间CFR,6个月时两组CFR均改善;托珠单抗组VCAM-1曲线下面积显著更高(中位数622 vs 609 ng/mL/小时,p=0.003),但未伴随CFR降低。

要点

  • 托珠单抗未影响住院期间CFR(3.4±0.8 vs 3.3±1.2,p=0.80)。
  • 6个月时两组CFR均显著改善。
  • 托珠单抗组VCAM-1曲线下面积显著更高(中位数622 vs 609 ng/mL/小时,p=0.003)。

核心结论

  • 托珠单抗未影响住院期间或6个月后的冠状动脉血流储备(CFR)。
  • 托珠单抗增加了住院期间VCAM-1水平,但未伴随这些患者CFR降低。

研究设计与样本

  • 本亚组研究为两中心、双盲、随机、安慰剂对照试验的一部分,评估单次托珠单抗在非ST段抬高型心肌梗死(NSTEMI)中的效应。
  • 117例患者评估了内皮细胞活化标志物(VCAM-1、细胞间黏附分子-1和血管性血友病因子)。
  • 其中42例患者(安慰剂组20例,托珠单抗组22例)测量了CFR。
  • 第1天至第3天之间连续7个时间点采集血样。
  • 住院期间及6个月后通过经胸超声心动图测量CFR。

主要发现

  • 住院期间CFR:托珠单抗组3.4±0.8 vs 安慰剂组3.3±1.2,p=0.80。
  • 6个月时两组CFR均显著改善。
  • VCAM-1曲线下面积:托珠单抗组中位数622 vs 安慰剂组609 ng/mL/小时,p=0.003。
  • VCAM-1与CFR的负相关仅见于安慰剂组(住院期间:r=-0.74,p<0.01;6个月:r=-0.59,p<0.01),托珠单抗组无此相关(住院期间:r=0.20,p=0.37;6个月:r=-0.28,p=0.20)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interleukin-6 (IL-6) is a driver of inflammation and associated endothelial cell activation in acute coronary syndromes. We evaluated the effect of the IL-6 receptor antagonist tocilizumab on coronary microvascular function and endothelial dysfunction measured by coronary flow reserve (CFR) and markers of endothelial cell activation in patients with non-ST-elevation myocardial infarction (NSTEMI). METHODS: This substudy was part of a two-centre, double-blind, randomised, placebo-controlled trial evaluating the effect of a single dose of tocilizumab in NSTEMI. Markers of endothelial cell activation (vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule-1 and von Willebrand factor) were assessed in 117 patients. In 42 of these patients, 20 assigned to placebo and 22 to tocilizumab, we measured CFR. Blood samples were obtained at seven consecutive time points between day 1 and 3. CFR was measured by transthoracic echocardiography during hospitalisation and after 6 months. RESULTS: Tocilizumab did not affect CFR during hospitalisation (tocilizumab: 3.4±0.8 vs placebo: 3.3±1.2, p=0.80). CFR improved significantly in both groups at 6 months. Patients in the tocilizumab group had significantly higher area under the curve for VCAM-1 (median 622 vs 609 ng/mL/hour, tocilizumab and placebo respectively, p=0.003). There were inverse correlations between VCAM-1 and CFR in the placebo (hospitalisation: r=-0.74, p<0.01, 6 months: r=-0.59, p<0.01), but not in the tocilizumab group (hospitalisation: r=0.20, p=0.37, 6 months r=-0.28, p=0.20). CONCLUSIONS: Tocilizumab did not affect CFR during hospitalisation or after 6 months. Tocilizumab increased VCAM-1 levels during hospitalisation, but this was not associated with reduced CFR in these patients.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Holte E, Kleveland O, Ueland T, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. 2017. PMID: 28432157. doi:10.1136/heartjnl-2016-310875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。